5-(2-Fluorophenyl) -1H-Pyrrole-3-Carbaldehyde CAS 881674-56-2 Vonoprazan Fumarate Munditia Intermedia ≥99.0%
Supple Vonoprazan Fumarate ac Related medium
5-(2-Fluorophenyl) pyrrole-3-Carboxaldehyde CAS 881674-56-2
Pyridine-3-Sulfony Chloride CAS 16133-25-8
Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2
| Nomen chemicum | 5-(2-Fluorophenyl) -1H-pyrrole-3-Carbaldehyde |
| Synonyma | Vonoprazan Fumarate (TAK-438) 3 |
| CAS Number | 881674-56-2 |
| CATTUS Number | RF-PI330 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C11H8FNO |
| M. Pondus | 189.19 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Flavo ad Brown pulveris |
| Liquescens punctum | 122.0~ 131.0℃ |
| Lepidium sativum: RT (HPLC) | Conformare cum Latin |
| Damnum de Siccatio | ≤0.50% |
| Residua de Ignition | ≤0.50% |
| Substantiae cognatae | |
| Puritas | ≥99.0% |
| Unam immunditiam | ≤0.50% |
| Totalis immunditias | ≤1.0% |
| Test Standard | Enterprise Standard |
| Consuetudinem | Intermedia Vonoprazan Fumarate (TAK-438) (CAS 881681-01-2) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.
5-(2-Fluorophenyl)-1H-pyrrole-3-Carbaldehyde (CAS 881674-56-2) fungitur synthetica praeparatione derivationum novarum pyrrolarum ac potassae-competitivae acidi obstructoris (P-CAB).5-(2-Fluorophenyl) pyrrole-3-Carboxaldehyde est medium Vonoprazan Fumarate (CAS 1260141-27-2).Vonoprazan fumarate (Takecab®), inventa et evoluta ab Takeda et Otsuka, ab PMDA Iaponiae mense Decembri 2014 probata est, et curatione ulceris gastrici, duodeni ulceris et reflux esophagitis indicatur.Vonoprazan fumaratus novam mechanismum actionis quae acidum potassium-competitivum obstructores habet, quae certatim ligamen potassii ad H+, K+-ATPase (etiam proton sentinae notae) in ultimo gradu acidi gastrici secretionis in cellulis parietalibus gastrici prohibent.Vonoprazan non inhibet Na+, K+-ATPase activitatem etiam in concentionibus 500 vicibus altioribus quam valorum suorum IC50 contra gastricam H+, K+-ATPase actionem.Praeterea medicamentum a secretoriis gastrici statu non caret, dissimili PPIs.
